EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA’s benefit to European citizens

Enabling science that serves patients

ENVI Committee hearing 25 April 2017

Medicines in Europe



- Single market for safe, effective and high-quality medicines benefits **patients**, **companies** and **academic research**
- **One** application, **one** evaluation, **one** marketing authorisation for new medicines in all EU member states
- EU regulatory system: **one set of rules and standards** applied throughout the lifecycle of a medicine
- EMA – knowledge hub bringing together the right **experts** from across the EU to do the right job at the right time

EMA – making the single market work for citizens

- Independent, transparent and evidence-based assessment from 4000 EU scientific experts

- Continuous safety monitoring of medicines
  -> fast and EU-wide action to protect public health

- Support to innovation and development of new medicines

- Patient involvement in decision-making

EMA – promoting public and animal health

Transparency that benefits research and innovation

Clinical Data Publication - EMA is the first regulator worldwide to release clinical reports that form the basis of our scientific recommendations

Safe medicines for European patients

EU Pharmacovigilance - one of the most advanced legal frameworks in the world enabling EMA to initiate EU-wide regulatory action based on continuous monitoring of medicines' safety

Addressing patients' unmet needs

EMA's "PRIME" provides early, proactive and enhanced support to developers of medicines that target an unmet medical need so that breakthroughs in medicines can reach patients quicker.

Thank you for your attention

Further information

European Medicines Agency
30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

60 ROME
PEACE
DEMOCRACY
SOLIDARITY

Follow us on **@EMA_News**